Diary - News All news Alizé Pharma reports positive results of AZP-531 on Prader-Willi syndrom

Alizé Pharma reports positive results of AZP-531 on Prader-Willi syndrom

Alizé Pharma SAS is an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases.

It announces today the top-line results of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi Syndrome (PWS).

This randomized, double-blind, placebo-controlled, European multicenter study was aimed at evaluating the safety, tolerab ility and efficacy of AZP-531 administered dailysubcutaneously for 14 days on food-related behavior, versus place.

Read the press release